Lanier Biotherapeutics Overview
- Year Founded
-
2000
- Status
-
Acquired/Merged
- Employees
-
9
- Latest Deal Type
-
Later Stage VC
- (Cancelled)
Lanier Biotherapeutics General Information
Description
Manufacturer of biotechnology products intended to support the selection, analysis, and synthesis of monoclonal antibodies. The company's products offer methods that obtain antibodies directly from the immune system of immunized mice and develop candidates for retinal, dermatological, and respiratory conditions, including anti-vascular endothelial growth factor and anti-interleukin monoclonal antibodies, enabling medical practitioners to access therapies with defined mechanisms of action.
Contact Information
Website
www.lanierbio.com(Operating Subsidiary)
Corporate Office
- P.O. Box 1071
- Jefferson, GA 30549
- United States
Corporate Office
- P.O. Box 1071
- Jefferson, GA 30549
- United States
Lanier Biotherapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 16. Later Stage VC | Cancelled | Generating Revenue | ||||
| 15. Merger/Acquisition | 30-Sep-2021 | Completed | Generating Revenue | |||
| 14. Later Stage VC | 04-Aug-2021 | Completed | Generating Revenue | |||
| 13. Grant | 20-Sep-2016 | Completed | Generating Revenue | |||
| 12. Later Stage VC | 05-Jan-2016 | Completed | Generating Revenue | |||
| 11. Grant | 10-Feb-2014 | Completed | Generating Revenue | |||
| 10. Grant | 15-Mar-2013 | Completed | Generating Revenue | |||
| 9. Grant | 01-Nov-2010 | Completed | Generating Revenue | |||
| 8. Grant | 01-Jan-2010 | $134K | $2.1M | Completed | Generating Revenue | |
| 7. Later Stage VC | 20-Jul-2008 | $2.1M | Completed | Generating Revenue |
Lanier Biotherapeutics Patents
Lanier Biotherapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025085538-A1 | Alarmin binding molecules and treatment of cancer | Inactive | 17-Oct-2023 | ||
| EP-4482522-A2 | Anti-alarmin binding molecules and treatment of pneumonitis | Pending | 25-Feb-2022 | ||
| EP-4482522-A4 | Anti-alarmin binding molecules and treatment of pneumonitis | Pending | 25-Feb-2022 | ||
| US-20250170238-A1 | Anti-alarmin binding molecules and treatment of pneumonitis | Pending | 25-Feb-2022 | ||
| WO-2023164649-A2 | Anti-alarmin binding molecules and treatment of pneumonitis | Inactive | 25-Feb-2022 | A61K39/3955 |
Lanier Biotherapeutics Signals
Lanier Biotherapeutics Former Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Advanced Technology Development Center | Accelerator/Incubator | Minority | ||
| Cato BioVentures | Corporate Venture Capital | Minority | ||
| Georgia Research Alliance | Not-For-Profit Venture Capital | Minority | ||
| Georgia Venture Partners | Venture Capital | Minority | ||
| National Heart, Lung, and Blood Institute | Government |
Lanier Biotherapeutics FAQs
-
When was Lanier Biotherapeutics founded?
Lanier Biotherapeutics was founded in 2000.
-
Where is Lanier Biotherapeutics headquartered?
Lanier Biotherapeutics is headquartered in Jefferson, GA.
-
What is the size of Lanier Biotherapeutics?
Lanier Biotherapeutics has 9 total employees.
-
What industry is Lanier Biotherapeutics in?
Lanier Biotherapeutics’s primary industry is Biotechnology.
-
Is Lanier Biotherapeutics a private or public company?
Lanier Biotherapeutics is a Private company.
-
What is Lanier Biotherapeutics’s current revenue?
The current revenue for Lanier Biotherapeutics is .
-
How much funding has Lanier Biotherapeutics raised over time?
Lanier Biotherapeutics has raised $4.9M.
-
Who are Lanier Biotherapeutics’s investors?
Advanced Technology Development Center, Cato BioVentures, Georgia Research Alliance, Georgia Venture Partners, and National Heart, Lung, and Blood Institute are 5 of 6 investors who have invested in Lanier Biotherapeutics.
-
Who acquired Lanier Biotherapeutics?
Lanier Biotherapeutics was acquired by Alloy Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process